Samsali Wart Remover

Description

The drug is identified by the SPL code 34089-3 and is presented as a white to off-white powder. Its chemical name is insert chemical name here. The formulation includes inactive ingredients, which are insert inactive ingredients here.

Uses and Indications

This drug is indicated for the removal of plantar warts, common warts, flat warts, corns, and calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended application frequency is twice daily, specifically in the morning and evening. For conditions primarily affecting the feet, it is advised to apply the product before bedtime. This timing helps to minimize friction during walking and enhances absorption.

Patients should continue the daily application for a duration of 2 weeks, or until the skin appears smooth and healthy. In cases of more severe conditions, an extended application period may be necessary to achieve optimal results.

Contraindications

Use of this product is contraindicated in patients with a known allergy to the formulation, particularly when applied to damaged skin in the facial area or around the eyes.

Warnings and Precautions

In the event of ingestion, immediate medical assistance should be sought, or the individual should contact a Poison Control Center without delay.

Healthcare professionals are advised to monitor patients for signs of an allergic reaction. Should any symptoms indicative of an allergic response manifest, it is imperative to discontinue use and consult a physician promptly. Additionally, if patients experience discomfort or any adverse effects during the course of treatment, they should be instructed to stop taking the medication and seek medical advice.

No specific laboratory tests or general precautions have been identified for this medication; however, vigilance in monitoring patient responses is essential to ensure safety and efficacy.

Side Effects

Patients may experience signs of an allergic reaction while using the product. Additionally, discomfort or other adverse effects may occur during use. It is important for patients to be aware of these potential reactions and to seek medical attention if they experience any severe or concerning symptoms. No specific side effects have been detailed in the available data, but monitoring for any unexpected reactions is advised.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Samsali Wart Remover (wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this product under adult supervision to ensure safe and effective use. Caregivers are advised to monitor children closely while administering the product to mitigate any potential risks associated with unsupervised use.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients, those intending to become pregnant, and breastfeeding individuals should consult their healthcare provider prior to using this medication. It is essential to evaluate the potential risks and benefits associated with treatment during pregnancy and lactation. Healthcare professionals are advised to consider the individual circumstances of each patient when making recommendations.

Lactation

Lactating mothers are advised to consult their healthcare provider if they are pregnant, intending to become pregnant, or breastfeeding. There is no specific data available regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, healthcare professionals should consider the potential risks and benefits when prescribing this medication to lactating mothers.

Renal Impairment

Patients with renal impairment may require a reduced dose of the medication. It is essential to assess creatinine clearance prior to the initiation of therapy in this population. Regular renal function tests are recommended for patients with existing kidney problems to monitor their condition effectively. Additionally, special monitoring is necessary for patients with significant renal impairment to avoid potential toxicity. Dosage adjustments may be warranted based on the severity of renal impairment to ensure safe and effective treatment.

Hepatic Impairment

Patients with hepatic impairment may experience altered metabolism of the drug, necessitating dosage adjustments to ensure safety and efficacy. It is essential to monitor liver function tests in this population to assess the degree of impairment and guide treatment decisions. Special precautions should be taken when administering the drug to patients with liver problems, as their compromised liver function may increase the risk of adverse effects or alter the pharmacokinetics of the medication.

Overdosage

In the absence of specific information regarding overdosage in the available sections of the drug insert, healthcare professionals are advised to exercise caution when administering the medication.

Should an overdosage occur, it is essential to monitor the patient closely for any potential adverse effects, even if they are not explicitly detailed in the drug insert. Symptoms of overdosage may vary and could include a range of physiological responses.

Management of overdosage should be supportive and symptomatic. Healthcare providers are encouraged to implement standard emergency protocols, which may include the following steps:

1. Assessment: Conduct a thorough evaluation of the patient's clinical status, including vital signs and neurological assessment.

2. Supportive Care: Provide appropriate supportive care tailored to the symptoms presented by the patient.

3. Consultation: In cases of suspected overdosage, consultation with a poison control center or a medical toxicologist is recommended for guidance on further management.

Due to the lack of specific overdosage information, it is imperative for healthcare professionals to remain vigilant and prepared to address any complications that may arise from an overdose of this medication.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients not to use the product around the eyes or on the facial area if they have a known allergy to it or if their skin is damaged.

Patients should be instructed to discontinue use if they experience any signs of an allergic reaction, discomfort, or adverse effects during application. Additionally, healthcare providers should emphasize the importance of avoiding eye contact while using the product. In the event that the product does come into contact with the eyes, patients should be directed to thoroughly rinse their eyes with water.

Storage and Handling

The product is supplied in a sealed container and should be stored at room temperature. It is essential to maintain the integrity of the seal until the product is ready for use to ensure optimal quality and efficacy.

Additional Clinical Information

The medication is administered topically, with a recommended application frequency of twice daily, in the morning and evening. For foot-related issues, it is advised to apply the medication before bedtime to reduce friction during walking and to enhance absorption.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Samsali Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)